| Drug Name |
Carfilzomib |
| Drug ID |
BADD_D00367 |
| Description |
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392] |
| Indications and Usage |
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.[L39392] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XG02 |
| DrugBank ID |
DB08889
|
| KEGG ID |
D08880
|
| MeSH ID |
C524865
|
| PubChem ID |
11556711
|
| TTD Drug ID |
D00UVA
|
| NDC Product Code |
76055-0035; 76075-103; 76075-101; 63552-009; 67262-0010; 42385-731; 76075-102; 63552-035; 54893-0037; 52076-6251; 55111-985; 11722-059 |
| UNII |
72X6E3J5AR
|
| Synonyms |
carfilzomib | PR-171 | PR171 | Kyprolis |
